Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00661479 · ClinicalTrials.gov registry record · Phase 1
An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa
A Phase 1 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00661479 is a Phase 1 study that has completed, run by Allergan. The registered enrollment target is 21 participants.
The verdict
NCT00661479, a Phase 1 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This exploratory, 12-month, ascending-dose study will evaluate the safety and effects on visual function of a single injection of Brimonidine intravitreal implant in one eye of patients with Retinitis Pigmentosa.
Interventions
- DRUG 400 µg Brimonidine Tartrate Implant
- DRUG 200 µg Brimonidine Tartrate Implant
- OTHER Sham (no implant)
- DRUG 100 µg Brimonidine Tartrate Implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-07 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00661479
The ClinicalTrials.gov registry entry for NCT00661479 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 400 µg Brimonidine Tartrate Implant is the first listed.
NCT00661479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00661479 about?
NCT00661479 is a clinical study titled "An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa". This exploratory, 12-month, ascending-dose study will evaluate the safety and effects on visual function of a single injection of Brimonidine intravitreal implant in one eye of patients with Retinitis Pigmentosa.
What is the current status of trial NCT00661479?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2008-07. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00661479?
The interventions under investigation include: 400 µg Brimonidine Tartrate Implant (DRUG), 200 µg Brimonidine Tartrate Implant (DRUG), Sham (no implant) (OTHER), 100 µg Brimonidine Tartrate Implant (DRUG).
Who is sponsoring clinical trial NCT00661479?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.